+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilar Monoclonal Antibodies Market by Molecule Class (Anti Cd20, Anti Her2, Anti Vascular Endothelial Growth Factor), Indication (Inflammatory Bowel Disease, Neutropenia, Oncology), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Biosimilar Monoclonal Antibodies Market by Molecule Class (Anti Cd20, Anti Her2, Anti Vascular Endothelial Growth Factor), Indication (Inflammatory Bowel Disease, Neutropenia, Oncology), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Biosimilar Monoclonal Antibodies Market by Molecule Class (Anti Cd20, Anti Her2, Anti Vascular Endothelial Growth Factor), Indication (Inflammatory Bowel Disease, Neutropenia, Oncology), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010903
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The biosimilar monoclonal antibodies market is transforming access to advanced biologic therapies, supporting healthcare systems as they adapt to cost pressures and evolving demand for evidence-based treatment options.

Market Snapshot: Biosimilar Monoclonal Antibodies at a Glance

The Biosimilar Monoclonal Antibodies Market grew from USD 9.47 billion in 2024 to USD 11.73 billion in 2025. It is expected to continue growing at a CAGR of 23.26%, reaching USD 33.22 billion by 2030. Increased adoption across major healthcare markets and the expiration of originator drug patents are accelerating competition and reshaping procurement strategies. The market’s strong trajectory is creating new openings for innovative alliances, robust supply chain strategies, and dynamic product launches, especially as regional regulations and reimbursement models mature.

Scope & Segmentation in the Biosimilar Monoclonal Antibodies Market

  • Molecule Classes: Anti CD20 agents; Anti HER2 drugs; Anti Vascular Endothelial Growth Factor products such as aflibercept, bevacizumab, ranibizumab; Colony Stimulating Factors including filgrastim and pegfilgrastim; TNF Inhibitors like adalimumab, etanercept, infliximab.
  • Indications: Treatments target inflammatory bowel diseases including Crohn disease and ulcerative colitis; neutropenia; oncology areas such as breast cancer, colorectal cancer, lung cancer; various forms of psoriasis; adult and juvenile idiopathic rheumatoid arthritis.
  • Dosage Forms: Available as liquid solutions, prefilled pens, prefilled syringes, and vials (liquid or lyophilized powder), offering flexibility for clinician and patient preference.
  • Distribution Channels: Comprise both offline and digital platforms, increasing reach and convenience for stakeholders.
  • End Users: Include hospital pharmacies (private, public), retail pharmacies (chain, independent), and specialty clinics—dermatology, oncology, rheumatology—ensuring wide accessibility.
  • Regional Markets: The Americas, Europe, Middle East & Africa, and Asia-Pacific feature distinct adoption drivers, including healthcare infrastructure, regulatory harmonization, government procurement policies, and local manufacturing initiatives.
  • Key Companies: Sandoz International GmbH, Pfizer Inc., Amgen Inc., Samsung Bioepis Co., Ltd., Celltrion, Inc., Biocon Ltd., Coherus BioSciences, Inc., Merck KGaA, Fresenius Kabi AG, and Viatris Inc. are among the primary industry participants advancing the field.

Key Takeaways for Senior Decision-Makers

  • Biosimilar monoclonal antibodies lower barriers to modern biologic treatment by mirroring efficacy and safety standards of original therapies, helping healthcare systems expand patient access while maintaining quality.
  • Manufacturing advances—including cell line optimization and process analytics—are streamlining production and accelerating time-to-market for new entrants, creating operational advantages and supporting diverse product pipelines.
  • Strategic partnerships, such as licensing and co-promotion agreements, support emerging players in leveraging established global distribution and tapping into commercial expertise, fostering healthy competition and improved market presence.
  • Original biologic manufacturers are adopting lifecycle management tactics and developing differentiated delivery formats to sustain competitive edge as biosimilar adoption rises across multiple therapeutic areas.
  • Healthcare providers benefit from expanded dosage formats and diversified distribution channels, increasing patient convenience and promoting overall adherence, which in turn supports payer acceptance and formulary inclusion strategies.
  • Geographic dynamics highlight how regulatory harmonization and procurement models drive biosimilar market growth; mature markets experience volume increases through tendering and competitive pricing, while emerging economies ramp up adoption via local manufacturing and public-private collaboration.

Tariff Impact: Strategic Implications of the 2025 U.S. Tariff Policy

The 2025 introduction of new U.S. tariffs adds complexity to biosimilar monoclonal antibody supply chains, influencing input costs and shifting sourcing strategies. Manufacturers are exploring nearshoring, renegotiating procurement contracts, and diversifying supplier bases to address tariff-induced uncertainty. Downstream, distributors and providers are prioritizing resilient logistics and investing in domestic manufacturing to minimize exposure. Payers adjust reimbursement frameworks to reflect rising costs, prompting stakeholders to reconsider coverage and contracting strategies in the United States market.

Methodology & Data Sources

This report builds on secondary research—including regulatory filings, peer-reviewed publications, and corporate disclosures—supported by primary interviews with executives, R&D leaders, and payers. Rigorous triangulation of supply chain data, clinical trial registries, and proprietary intelligence ensures robust analysis. All findings undergo peer review for consistency and accuracy, using scenario modeling and sensitivity analysis to test assumptions against changing market forces.

Why This Report Matters for Senior Executives

  • Gain actionable insights into evolving biosimilar monoclonal antibody strategies to inform investment and partnership decisions.
  • Understand region-specific challenges and opportunities—from regulatory policy to supply chain design—empowering confident market entry, expansion, and risk mitigation.

Conclusion

As the biosimilar monoclonal antibody market evolves, decision-makers equipped with operational insight and regional intelligence are best placed to drive sustainable adoption. Targeted strategies that align innovation, partnerships, and evidence-based approaches will inform future industry leadership and enhance patient care worldwide.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of interchangeability designations on biosimilar monoclonal antibody adoption rates
5.2. Evolving regulatory frameworks for extrapolation of indications in biosimilar mAbs
5.3. Competitive pricing dynamics influenced by value-based contracting in mAb biosimilars
5.4. Supply chain resilience strategies amid global bioreactor capacity constraints
5.5. Advances in analytical similarity assessments using high-resolution mass spectrometry
5.6. Real-world evidence generation supporting biosimilar mAb safety and immunogenicity profiles
5.7. Emerging partnerships between biotechs and CMOs for accelerated biosimilar mAb development
5.8. Adoption of patient support programs to enhance biosimilar monoclonal antibody adherence
5.9. Integration of digital health tools for monitoring therapeutic outcomes of mAb biosimilars
5.10. Impact of patent litigations on biosimilar monoclonal antibody market entry timelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biosimilar Monoclonal Antibodies Market, by Molecule Class
8.1. Introduction
8.2. Anti Cd20
8.3. Anti Her2
8.4. Anti Vascular Endothelial Growth Factor
8.4.1. Aflibercept
8.4.2. Bevacizumab
8.4.3. Ranibizumab
8.5. Colony Stimulating Factors
8.5.1. Filgrastim
8.5.2. Pegfilgrastim
8.6. Tnf Inhibitors
8.6.1. Adalimumab
8.6.2. Etanercept
8.6.3. Infliximab
9. Biosimilar Monoclonal Antibodies Market, by Indication
9.1. Introduction
9.2. Inflammatory Bowel Disease
9.2.1. Crohn Disease
9.2.2. Ulcerative Colitis
9.3. Neutropenia
9.4. Oncology
9.4.1. Breast Cancer
9.4.2. Colorectal Cancer
9.4.3. Lung Cancer
9.5. Psoriasis
9.5.1. Plaque Psoriasis
9.5.2. Psoriatic Arthritis
9.6. Rheumatoid Arthritis
9.6.1. Adult Rheumatoid Arthritis
9.6.2. Juvenile Idiopathic Arthritis
10. Biosimilar Monoclonal Antibodies Market, by Dosage Form
10.1. Introduction
10.2. Liquid Solution
10.3. Prefilled Pen
10.4. Prefilled Syringe
10.5. Vial
10.5.1. Liquid Vial
10.5.2. Lyophilized Powder
11. Biosimilar Monoclonal Antibodies Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Biosimilar Monoclonal Antibodies Market, by End User
12.1. Introduction
12.2. Hospital Pharmacy
12.2.1. Private Hospital
12.2.2. Public Hospital
12.3. Retail Pharmacy
12.3.1. Chain Pharmacy
12.3.2. Independent Pharmacy
12.4. Specialty Clinics
12.4.1. Dermatology Clinic
12.4.2. Oncology Center
12.4.3. Rheumatology Clinic
13. Americas Biosimilar Monoclonal Antibodies Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Biosimilar Monoclonal Antibodies Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Biosimilar Monoclonal Antibodies Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Sandoz International GmbH
16.3.2. Pfizer Inc.
16.3.3. Amgen Inc.
16.3.4. Samsung Bioepis Co., Ltd.
16.3.5. Celltrion, Inc.
16.3.6. Biocon Ltd.
16.3.7. Coherus BioSciences, Inc.
16.3.8. Merck KGaA
16.3.9. Fresenius Kabi AG
16.3.10. Viatris Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RESEARCHAI
FIGURE 26. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RESEARCHSTATISTICS
FIGURE 27. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RESEARCHCONTACTS
FIGURE 28. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI CD20, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI CD20, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI HER2, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI HER2, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY FILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ETANERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CROHN DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADULT RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADULT RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED PEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DERMATOLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DERMATOLOGY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOLOGY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 199. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 200. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 201. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2024 (USD MILLION)
TABLE 202. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2025-2030 (USD MILLION)
TABLE 203. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2024 (USD MILLION)
TABLE 204. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2025-2030 (USD MILLION)
TABLE 205. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
TABLE 210. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2030 (USD MILLION)
TABLE 211. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 212. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 213. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 214. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 215. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 216. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 217. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 218. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 219. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 220. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 221. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 226. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 227. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 228. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 229. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 230. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 231. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 232. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 233. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2024 (USD MILLION)
TABLE 234. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2025-2030 (USD MILLION)
TABLE 235. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2024 (USD MILLION)
TABLE 236. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2025-2030 (USD MILLION)
TABLE 237. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
TABLE 242. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2030 (USD MILLION)
TABLE 243. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 244. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 245. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 246. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 247. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 248. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 249. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 250. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 251. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 252. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 253. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 258. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 259. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 260. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 261. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 262. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COLONY STIMULATING FACTORS, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL BIO

Samples

Loading
LOADING...

Companies Mentioned

  • Sandoz International GmbH
  • Pfizer Inc.
  • Amgen Inc.
  • Samsung Bioepis Co., Ltd.
  • Celltrion, Inc.
  • Biocon Ltd.
  • Coherus BioSciences, Inc.
  • Merck KGaA
  • Fresenius Kabi AG
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.73 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.22 Billion
Compound Annual Growth Rate23.2%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Psoriasis Biosimilar Market by Product Type (Fusion Proteins, Monoclonal Antibodies), Route of Administration (Intravenous Administration, Subcutaneous Administration), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Psoriasis Biosimilar Market by Product Type (Fusion Proteins, Monoclonal Antibodies), Route of Administration (Intravenous Administration, Subcutaneous Administration), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Biosimilar Monoclonal Antibody - Global Strategic Business Report - Product Image

Biosimilar Monoclonal Antibody - Global Strategic Business Report

  • Report
  • 235 Pages
  • Global
From
Similar Biological Medicinal Products Market by Product Type (Blood Factors, Cytokines, Hormones), Indication (Autoimmune Disorders, Infectious Diseases, Oncology), Therapeutic Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Similar Biological Medicinal Products Market by Product Type (Blood Factors, Cytokines, Hormones), Indication (Autoimmune Disorders, Infectious Diseases, Oncology), Therapeutic Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market Report 2025 - Product Image

Biosimilar Monoclonal Antibodies Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035 - Product Image

Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035

  • Report
  • 392 Pages
  • Global
From

About the Market

Biosimilar Monoclonal Antibodies (mAbs) are biotechnological products that are similar to existing monoclonal antibodies (mAbs) that are already approved for use in humans. Biosimilar mAbs are developed using recombinant DNA technology and are designed to have the same structure and function as the original mAbs. Biosimilar mAbs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. They are also used in research and development of new treatments. The biosimilar mAbs market is growing rapidly due to the increasing demand for mAbs in the treatment of various diseases. The market is expected to continue to grow as more mAbs are developed and approved for use in humans. Additionally, the increasing demand for mAbs in research and development is expected to drive the growth of the market. Some companies in the biosimilar mAbs market include Amgen, Biogen, Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.